Clinicopathological and prognostic significance of Ki-67, caspase-3 and p53 expression in gastric carcinomas

Oncology Letters

Volumn 6, Issue 5, 2013, Pages 1277-1284

  Xiao, Li Jun ^a,b   Zhao, Shuang ^a,b   Zhao, En Hong ^b   Zheng, Xin ^b   Gou, Wen Feng ^a   Takano, Yasuo ^c   Zheng, Hua Chuan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b CHENGDE MEDICAL COLLEGE   (China)

^c KANAGAWA CANCER CENTER   (Japan)

Author keywords

Caspase 3; Clinicopathological significance; Gastric carcinoma; Ki 67; p53; Prognosis

Indexed keywords

CASPASE 3; KI 67 ANTIGEN; PROTEIN P53;

AGED; ARTICLE; CANCER STAGING; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; STOMACH CARCINOMA; SURVIVAL TIME; TISSUE MICROARRAY; TUMOR INVASION; TUMOR VOLUME;

EID: 84884471782     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1532     Document Type: Article

References (37)

1. Rivera F, Vega-Villegas ME and López-Brea MF: Chemotherapy of advanced gastric cancer. Cancer Treat Rev 33: 315-324, 2007.
2. Kelley JR and Duggan JM: Gastric cancer epidemiology and risk factors. J Clin Epidemiol 56: 1-9, 2003.
3. Scholzen T and Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol 182: 311-322, 2000.
4. Endl E and Gerdes J: The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res 257: 231-237, 2000.
5. Chino O, Osamura Y, Kise Y, Nishi T, Shimada H, Tanaka M, KijimaH and Makuuchi H: Acceleration of the proliferative activity of esophageal carcinoma with invasion beyond the muscularis mucosae; immunohistochemical analysis using MIB-1 for the Ki-67 antigen. Tokai J Exp Clin Med 32: 115-120, 2007.
6. Zheng HC, Sun JM, Wei ZL, Yang XF, Zhang YC and XinY: Expression of Fas ligand and caspase-3 contributes to formation of immune escape in gastric cancer. World J Gastroenterol9: 1415-1420, 2003.
7. Kumar S: The apoptotic cysteine protease CPP32. Int J Biochem Cell Biol 29: 393-396, 1997.
8. Sternberg MJ, Bates PA, Kelley LA and MacCallumRM: Progress in protein structure prediction: assessment of CASP3. Curr Opin Struct Biol 9: 368-373, 1999.
9. Soussi T: The p53 pathway and human cancer. Br J Surg92: 1331-1332, 2005.
10. Marreiros A, Dudgeon K, Dao V, Grimm MO, Czolij R, Crossley M and Jackson P: KAI1 promoter activity is dependent on p53, junB and AP2: evidence for a possible mechanism underlying loss of KAI1 expression in cancer cells. Oncogene24: 637-649, 2005.
11. Ito R, Nakayama H, Yoshida K, Oda N and Yasui W: Loss of maspin expression is associated with development and progression of gastric carcinoma with p53 abnormality. Oncol Rep 12: 985-990, 2004.
12. Ala-aho R, Grénman R, Seth P and Kähäri VM: Adenoviral delivery of p53 gene suppresses expression of collagenase-3 (MMP-13) in squamous carcinoma cells. Oncogene21: 1187-1195, 2002.
13. Yan C, Wang H and Boyd DD: ATF3 represses 72-kDa type IV collagenase (MMP-2) expression by antagonizing p53-dependent transactivation of the collagenase promoter. J Biol Chem277: 10804-10812, 2002.
14. Loging WT and Reisman D: Inhibition of the putative tumor suppressor gene TIMP-3 by tumor-derived p53 mutants and wildtype p53. Oncogene18: 7608-7615, 1999.
15. Chen SL, Wu YS, Shieh HY, Yen CC, Shen JJ and LinKH: P53 is a regulator of the metastasis suppressor gene Nm23-H1. Mol Carcinog36: 204-214, 2003.
16. de la Fuente MT, Casanova B, Cantero E, Hernández del CerroM, Garcia-Marco J, Silva A and Garcia-Pardo A: Involvement of p53 in alpha4beta1 integrin-mediated resistance of B-CLL cells to fludarabine. Biochem Biophys Res Commun 311: 708-712, 2003.
17. Zheng H, Tsuneyama K, Cheng C, Takahashi H, Cui Z, MuraiY, Nomoto K and Takano Y: An immunohistochemical study of P53 and Ki-67 in gastrointestinal adenoma and adenocarcinoma using tissue microarray. Anticancer Res 26: 2353-2360, 2006.
18. Sobin LH and Wittekind CH (eds): TNM Classification of Malignant Tumors. 6th edition. John Wiley and Sons, Hoboken, NJ, 2002.
19. Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, MiwaS, Tsuneyama K and Takano Y: Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: an immunostaining study on the tissue microarray. J Clin Pathol60: 273-277, 2007.
20. Zheng HC, Li XH, Hara T, Masuda S, Yang XH, GuanYF and Takano Y: Mixed-type gastric carcinomas exhibit more aggressive features and indicate the histogenesis of carcinomas. Virchows Arch 452: 525-534, 2008.
21. Kumada T, Tsuneyama K, Hatta H, Ishizawa S and TakanoY: Improved 1-h rapid immunostaining method using intermittent microwave irradiation: practicability based on 5 years application in Toyama Medical and Pharmaceutical University Hospital. Mod Pathol 17: 1141-1149, 2004.
22. Czyzewska J, Guzińska-Ustymowicz K, Pryczynicz A, KemonaA and Bandurski R: Immunohistochemical evaluation of Ki-67, PCNA and MCM2 proteins proliferation index (PI) in advanced gastric cancer. Folia Histochem Cytobiol 47: 289-296, 2009.
23. Lazǎr D, Tǎban S, Sporea I, Dema A, Cornianu M, Lazǎr E, Goldiş A and Vernic C: Ki-67 expression in gastric cancer. Results from a prospective study with long-term follow-up. Rom J Morphol Embryol 51: 655-661, 2010.
24. Lee HE, Kim MA, Lee BL and Kim WH: Low Ki-67 proliferation index is an indicator of poor prognosis in gastric cancer. J Surg Oncol 102: 201-206, 2010.
25. Joo YE, Chung IJ, Park YK, Koh YS, Lee JH, Park CH, Lee WS, Kim HS, Choi SK, Rew JS, Park CS and Kim SJ: Expression of cyclooxygenase-2, p53 and Ki-67 in gastric cancer. J Korean Med Sci 21: 871-876, 2006.
26. Oshima CT, Iriya K and Forones NM: Ki-67 as a prognostic marker in colorectal cancer but not in gastric cancer. Neoplasma52: 420-424, 2005.
27. Kikuyama S, Kubota T, Shimizu K and Miyakita M: Ki-67 antigen expression in relation to clinicopathological variables and prognosis in gastric cancer. Oncol Rep 5: 867-870, 1998.
28. Xu L, Zhang SM, Wang YP, Zhao FK, Wu DY and YanX: Relationship between DNA ploidy, expression of Ki-67 antigen and gastric cancer metastasis. World J Gastroenterol 5: 10-11, 1999.
29. He WL, Li YH, Yang DJ, Song W, Chen XL, Liu FK, WangZ, LiW, Chen W, Chen CY, He YL and Zhan WH: Combined evaluation of centromere protein H and Ki-67 as prognostic biomarker for patients with gastric carcinoma. Eur J Surg Oncol39: 141-149, 2013.
30. Stepień A, Izdebska M and Grzanka A: The types of cell death. Postepy Hig Med Dosw (Online) 61: 420-428, 2007 (In Polish).
31. Li YH, Wang C, Meng K, Chen LB and Zhou XJ: Influence of survivin and caspase-3 on cell apoptosis and prognosis in gastric carcinoma. World J Gastroenterol 10: 1984-1988, 2004.
32. Hoshi T, Sasano H, Kato K, Yabuki N, Ohara S, Konno R, AsakiS, Toyota T, Tateno H and Nagura H: Immunohistochemistry of Caspase3/CPP32 in human stomach and its correlation with cell proliferation and apoptosis. Anticancer Res 18: 4347-4353, 1998.
33. Isobe N, Onodera H, Mori A, Shimada Y, Yang W, YasudaS, Fujimoto A, Ooe H, Arii S, Kitaichi M and Imamura M: Caspase-3 expression in human gastric carcinoma and its clinical significance. Oncology 66: 201-209, 2004.
34. Steele RJ and Lane DP: P53 in cancer: a paradigm for modern management of cancer. Surgeon 3: 197-205, 2005.
35. Gonçalves AR, Carneiro AJ, Martins I, de Faria PA, Ferreira MA, de Mello EL, Fogaça HS, Elia CC and de Souza HS: Prognostic significance of p53 protein expression in early gastric cancer. Pathol Oncol Res 17: 349-355, 2011.
36. Wang L, Zhang XY, Xu L, Liu WJ, Zhang J and ZhangJP: Expression and significance of p53 and mdm2 in atypical intestinal metaplasia and gastric carcinoma. Oncol Lett2: 707-712, 2011.
37. Tzanakis NE, Peros G, Karakitsos P, GiannopoulosGA, Efstathiou SP, Rallis G, Tsigris C, Kostakis A and Nikiteas NI: Prognostic significance of p53 and Ki67 proteins expression in Greek gastric cancer patients. Acta Chir Belg 109: 606-611, 2009.